This Week in CRC Research — May 31, 2026
Weekly colorectal cancer research intelligence
her2
A collection of 6 issues
Prior anti-EGFR therapy affects HER2-targeted treatment outcomes
Skip to content
The CRC Digest
▸ TREATMENT
Prior anti-EGFR therapy affects HER2-targeted treatment outcomes — ESMO Open
An integrated analysis of the TRIUMPH and MyPathway studies examined how prior treatment with anti-EGFR (epidermal growth factor receptor) therapy affects the effectiveness of pertuzumab plus trastuzumab in HER2-amplified metastatic colorectal cancer. The study
CRC Research Update — May 29, 2026
Today's colorectal cancer research highlights
Baseline ctDNA profiling informs HER2-targeted therapy outcomes
Skip to content
The CRC Digest
Baseline ctDNA profiling informs HER2-targeted therapy outcomes
TRIUMPH/MyPathway analysis shows baseline circulating tumor DNA and prior anti-EGFR therapy affect pertuzumab plus trastuzumab efficacy in HER2-amplified metastatic colorectal cancer. (ESMO Open)
This content is informational only and does not constitute medical advice.
Always consult
CRC Research Update — May 24, 2026
Today's colorectal cancer research highlights
CRC Research Update — May 12, 2026
Today's colorectal cancer research highlights